drugset / Trial / NCT05982314
Extension Safety and Immunogenicity Study of GPNV-001
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A 6 and 12 month safety and immunogenicity study of participants in study GPNV-001, a novel whole-cell pneumococcal vaccine.
Timeline
- Start
- 2023-07-17
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gamma-PN3 | Vaccine | 50 ug | — |
| Subject | Gamma-PN3 | Vaccine | 250 ug | — |
| Subject | Gamma-PN3 | Vaccine | 1000 ug | — |
| Comparator | Pneumovax 23 | Vaccine | 0.5 ml | — |
| Comparator | Prevnar 13 | Vaccine | 0.5 ml | — |